Guggenheim Maintains Buy on C4 Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $7 to $6.
Guggenheim analyst Michael Schmidt maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $7 to $6.